RT Journal Article
SR Electronic
T1 Trans Cohorts Metabolomic Modulation Following Long-Term Successful Therapy in HIV-Infection
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.07.14.21260539
DO 10.1101/2021.07.14.21260539
A1 Mikaeloff, Flora
A1 Svensson-Akusjärvi, Sara
A1 Ikomey, George Mondinde
A1 Krishnan, Shuba
A1 Sperk, Maike
A1 Gupta, Soham
A1 Vega Magdaleno, Gustavo Daniel
A1 Escós, Alejandra
A1 Lyonga, Emilia
A1 Okomo, Marie Claire
A1 Tagne, Claude Tayou
A1 Babu, Hemalatha
A1 Lorson, Christian L
A1 Végvári, Ákos
A1 Banerjea, Akhil C.
A1 Kele, Julianna
A1 Hanna, Luke Elizabeth
A1 Singh, Kamal
A1 de Magalhães, João Pedro
A1 Benfeitas, Rui
A1 Neogi, Ujjwal
YR 2021
UL http://medrxiv.org/content/early/2021/07/18/2021.07.14.21260539.abstract
AB Despite successful combination antiretroviral therapy (cART), persistent low-grade immune activation together with inflammation and toxic antiretroviral drugs can lead to long-lasting metabolic adaptation in people living with HIV (PLWH). The successful short-term cART reported abnormalities in the metabolic reprogramming in PLWH, but the long-term consequences are unknown. This study investigated alterations in the plasma metabolic profiles by comparing PLWH and matched HIV-negative controls (HC) from Cameroon and India. We used untargeted and targeted LC-MS/MS-based metabolic profiling in PLWH with long-term (>5years) successful therapy in a trans cohorts’ approach. Advanced statistical and bioinformatics analyses showed altered amino acid metabolism, more specifically to glutaminolysis in PLWH with therapy than HIV-negative controls that can lead to excitotoxicity in both the cohorts. A significantly lower level of neurosteroids was observed in both cohorts and could potentiate neurological impairments in PLWH. The modulation of cellular glutaminolysis promoted increased cell death and latency reversal in pre-monocytic HIV-1 latent cell model U1, which may be essential for the clearance of the inducible reservoir in HIV-integrated cells. Our patient-based metabolomics and in vitro study, therefore, highlight the importance of altered glutaminolysis in PLWH that can be linked accelerated neurocognitive aging and metabolic reprogramming in latently infected cells.Competing Interest StatementC.L.L. is the co-founder and chief scientific officer for Shift Pharmaceuticals. The authors have declared that no conflict of interest exists.Clinical TrialThis is observational studyFunding StatementThe study is supported by the Swedish Research Council (2017-01330 and 2018-06156), Karolinska Institutet Stiftelser och Fonder (2020-01554), and Ake Wiberg Stiftelse grant (M18-0021). Swedish Physicians Against AIDS Foundation (FOb20170004) and Jeanssons Stiftelser (JS2016-0185) to UN. MS acknowledges the support received from Swedish Physicians Against AIDS Foundation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Cameroon study was approved by the Cameroon National Ethics Committee for Human Research with Ethical clearance NO2019/08-198-CE/CNERSH/SP. The Indian study was approved by the Institutional Ethics Committee of the National Institute for Research in Tuberculosis (NIRT IEC No: 2015023) and the Institutional Review Board of the Government Hospital for Thoracic Medicine (GHTM-27102015) Chennai, India. Ethical approval by Etikprovningsmyndigheten (Sweden) was waived off because of the anonymized data (Dnr 2019-05086). Written informed consent was obtained from all study participants prior inclusion and kept at the respective sites.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll the data available as supplementary file within manuscript